Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Research & Development (2020 - 2025)

NeuroPace (NPCE) has 6 years of Research & Development data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Research & Development rose 16.15% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $27.9 million, up 17.9%, while the annual FY2025 figure was $27.9 million, 17.9% up from the prior year.
  • Research & Development reached $7.0 million in Q4 2025 per NPCE's latest filing, up from $6.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $7.4 million in Q1 2025 and bottomed at $4.1 million in Q1 2021.
  • Average Research & Development over 5 years is $5.6 million, with a median of $5.6 million recorded in 2022.
  • The widest YoY moves for Research & Development: up 36.44% in 2021, down 15.17% in 2021.
  • A 5-year view of Research & Development shows it stood at $5.3 million in 2021, then dropped by 4.79% to $5.1 million in 2022, then grew by 5.66% to $5.4 million in 2023, then increased by 12.52% to $6.0 million in 2024, then grew by 16.15% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $7.0 million in Q4 2025, $6.6 million in Q3 2025, and $6.8 million in Q2 2025.